Sun. Mar 7th, 2021


But concerns have been raised over the efficacy of Covaxin because the

regulator’s emergency approval came before the completion of Phase 3 clinical trials. The regulator and the manufacturer have said the vaccine is safe, and that the efficacy data would be available by February.



Source link